Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Mar 6;82(7):1300–1304. doi: 10.1054/bjoc.1999.1095

Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells

A Skladanowski 1, J Konopa 1
PMCID: PMC2374491  PMID: 10755405

Abstract

We show here that mitoxantrone and ametantrone induce interstrand DNA cross-links in HeLa S3cells. These cross-links were observed only in cellular system suggesting that metabolism of the drugs is a necessary step leading to DNA cross-linking. Biologically inactive analogue of mitoxantrone, compound NSC 321458, did not induce cross-links in DNA of tumour cells which suggests that DNA cross-linking is associated with the cytotoxic and anti-tumour activity of these compounds. © 2000 Cancer Research Campaign

Keywords: aminoanthraquinones, mitoxantrone, mechanism of action, DNA cross-linking, covalent binding, metabolism

Full Text

The Full Text of this article is available as a PDF (66.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cholody W. M., Martelli S., Konopa J. 8-Substituted 5-[(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. Synthesis and biological activity. J Med Chem. 1990 Oct;33(10):2852–2856. doi: 10.1021/jm00172a028. [DOI] [PubMed] [Google Scholar]
  2. Cholody W. M., Martelli S., Paradziej-Lukowicz J., Konopa J. 5-[(Aminoalkyl)amino]imidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity. J Med Chem. 1990 Jan;33(1):49–52. doi: 10.1021/jm00163a009. [DOI] [PubMed] [Google Scholar]
  3. Dackiewicz P., Skladanowski A., Konopa J. 32P-postlabelling analysis of adducts formed by mitoxantrone and ametantrone with DNA and homopolydeoxyribonucleotides after enzymatic activation. Chem Biol Interact. 1995 Nov 17;98(2):153–166. doi: 10.1016/0009-2797(95)03643-1. [DOI] [PubMed] [Google Scholar]
  4. Ehninger G., Schuler U., Proksch B., Zeller K. P., Blanz J. Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet. 1990 May;18(5):365–380. doi: 10.2165/00003088-199018050-00003. [DOI] [PubMed] [Google Scholar]
  5. Fisher G. R., Patterson L. H. DNA strand breakage by peroxidase-activated mitoxantrone. J Pharm Pharmacol. 1991 Jan;43(1):65–68. doi: 10.1111/j.2042-7158.1991.tb05455.x. [DOI] [PubMed] [Google Scholar]
  6. Fry D. W. Biochemical pharmacology of anthracenediones and anthrapyrazoles. Pharmacol Ther. 1991 Oct;52(1):109–125. doi: 10.1016/0163-7258(91)90089-5. [DOI] [PubMed] [Google Scholar]
  7. Glisson B. S., Killary A. M., Merta P., Ross W. E., Siciliano J., Siciliano M. J. Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids. Cancer Chemother Pharmacol. 1992;31(2):131–138. doi: 10.1007/BF00685100. [DOI] [PubMed] [Google Scholar]
  8. Konopa J. Adriamycin and daunomycin induce interstrand DNA crosslinks in Hela S3 Cells. Biochem Biophys Res Commun. 1983 Feb 10;110(3):819–826. doi: 10.1016/0006-291x(83)91035-5. [DOI] [PubMed] [Google Scholar]
  9. Mewes K., Blanz J., Ehninger G., Gebhardt R., Zeller K. P. Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates. Cancer Res. 1993 Nov 1;53(21):5135–5142. [PubMed] [Google Scholar]
  10. Reszka K., Hartley J. A., Kolodziejczyk P., Lown J. W. Interaction of the peroxidase-derived metabolite of mitoxantrone with nucleic acids. Evidence for covalent binding of 14C-labeled drug. Biochem Pharmacol. 1989 Dec 1;38(23):4253–4260. doi: 10.1016/0006-2952(89)90523-6. [DOI] [PubMed] [Google Scholar]
  11. Skladanowski A., Konopa J. Interstrand DNA crosslinking induced by anthracyclines in tumour cells. Biochem Pharmacol. 1994 Jun 15;47(12):2269–2278. doi: 10.1016/0006-2952(94)90265-8. [DOI] [PubMed] [Google Scholar]
  12. Skladanowski A., Konopa J. Relevance of interstrand DNA crosslinking induced by anthracyclines for their biological activity. Biochem Pharmacol. 1994 Jun 15;47(12):2279–2287. doi: 10.1016/0006-2952(94)90266-6. [DOI] [PubMed] [Google Scholar]
  13. Smith P. J., Morgan S. A., Fox M. E., Watson J. V. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem Pharmacol. 1990 Nov 1;40(9):2069–2078. doi: 10.1016/0006-2952(90)90237-f. [DOI] [PubMed] [Google Scholar]
  14. Sundman-Engberg B., Tidefelt U., Gruber A., Paul C. Intracellular concentrations of mitoxantrone in leukemic cells in vitro vs in vivo. Leuk Res. 1993 Apr;17(4):347–352. doi: 10.1016/0145-2126(93)90022-d. [DOI] [PubMed] [Google Scholar]
  15. Zwelling L. A., Hinds M., Chan D., Mayes J., Sie K. L., Parker E., Silberman L., Radcliffe A., Beran M., Blick M. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J Biol Chem. 1989 Oct 5;264(28):16411–16420. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES